하루동안 이 창을 열지 않음  
바이오노트
Bridging animal health and diagnosis
Through unrivaled technology
  • 1
  • 3
Core technology
Ceaseless challenges and changes
Innovative bio-technology
  • 2
  • 3
Bio-contents
Solution Partner for Healthy
Coexistence of Humans and Animals
  • 3
  • 3
Global leader
    PRODUCT Introducing BIONOTE’s Products.
    • Rapid Immunoassay
      Rapid
    • Fluorescence Immunoassay
      Vcheck F
    • Enzyme Immunoassay
      ELISA
    • Molecular Diagnostics
      Vcheck M
    • Biochemistry
      Vcheck C
    NEWS Stay in the know of the latest Bionote updates. More
    USDA Approves Bionote’s Canine Heartworm Test Kit – Q2 2024

      ▶The global company Bionote, specializing in bio-content and animal diagnostics, announced on the 13th of May that its product, the 'Rapid CHW Ag 2.0' antigen diagnostic kit for canine heartworm, has obtained approval for sale from the United States Department of Agriculture (USDA).   Consequently, the product can be sold and distributed within the United States through Bionote's U.S. subsidiary, Bionote USA. Canine heartworm disease, transmitted primarily by mosquitoes, is a representative parasitic infectious disease in dogs. Heartworms, which primarily parasitize the pulmonary arteries, can lead to severe cardiovascular diseases and, in severe cases, death. It takes 6 to 7 months for the microfilariae transmitted by mosquitoes to grow into adult worms inside the dog's body. Clinical symptoms often do not immediately appear, which can lead to delayed diagnosis. Therefore, the American Heartworm Society (AHS) recommends monthly heartworm prevention and testing for heartworm infection at least once a year. Bionote's Canine Heartworm Antigen diagnostic kit can detect even a very small number of female worms (1 to 5 worms) and provides test results within 10 minutes. The newly approved 'Rapid CHW Ag 2.0' product is an upgraded version with a more compact design, making it even more suitable for on-site testing compared to the previously sold 'Rapid CHW Ag 1.0'. A Bionote representative stated, "According to research conducted at the University of Florida, the product has demonstrated a sensitivity and specificity of over 100% compared to the gold standard test, proving its high accuracy." They further stated, "The United States is a large market that accounts for over 40% of the global animal diagnostic testing market. We will continue to expand our presence in the U.S. market through further USDA product registrations, maximizing the sales force of our U.S. subsidiary, and collaborating with partners.

    2024.05.20
    BIONOTE launches a new cartridge for the diagnosis of two feline retroviruses.

        ▶Planning to maximize the market share in on-site POC molecular diagnostics by expanding the product portfolio.BIONOTE announced on the 5th of March that they have launched ‘Vcheck M FIV/FeLV’ which is for diagnosing Feline Immunodeficiency Virus (FIV) / Feline Leukemia Virus (FeLV). M10 is an automatic analyzer that can perform both nucleic acid extraction and PCR, which previously needed to be performed separately using two different machines. The test procedure is simple enough for any veterinarian to perform on-site at the animal hospitals without separate prior training. Furthermore, depending on the user's needs, they can customize how many modules they would like to use, up to a maximum of 8, making the M10 suitable for small hospitals, large hospitals, and even labs. A BIONOTE Spokesperson commented, “Following the launch of Feline Immunodeficiency Virus (FIV) and Feline Leukemia Virus (FeLV) cartridge, we will now be actively expanding the export internationally starting this month.” And that “We will accelerate the sales activity with 'Canine Vector 8 panel' and 'Canine Anemia 8 panel’ and strengthen our portfolio with the POC molecular diagnostic products, including 'Diarrhea 8 panel', which will be released this year. Our goal is to maximize our global market share in the veterinary field of molecular diagnostics as well”. Meanwhile, BIONOTE also aims to domestically launch a diagnostic cartridge with Babesia gibsoni which is known as causing a fatal tick-borne disease in dogs. BIONOTE is currently developing various test panels such as respiratory, anemia-causing pathogens and panels for livestock animals.

    2024.03.05
    BIONOTE Accelerates Expansion into North American Market Through VMX Conference

    ▶ BIONOTE promoted its products and provided lectures by prominent veterinarians about their experiences of applying Vcheck F to clinical settings ▶ Strengthen veterinary network across all areas of the U.S. to expand market share    Global leader in Veterinary Diagnostics and Biological Raw Materials BIONOTE Inc. announced on the 19th of January that its US Branch, BIONOTE USA, participated in VMX (Veterinary Meeting & EXPO), one of the largest veterinary conferences in the world held in Orlando, Florida between the 13th and 17th of January (local time). ​The VMX Conference is held in Orlando, Florida every year with over 15,000 members of the veterinary industry such as veterinarians, veterinary students, and veterinary technicians attending for various exchanges. Further, prominent speakers give lectures and companies unveil new products and technologies for animal clinics at the event.*Veterinary technicians: helps veterinarians in diagnosing patients effectively and performs surgery preparations, surgical assistance, and postoperative recovery observations. BIONOTE focused on promoting their point of care fluorescent immunoassay analyzer 'Vcheck F V200', which is the number 1 product globally in terms of market share, along with cardiac disease-related biomarker test reagents such as 'NT-proBNP', 'TnI' and hormone biomarker test reagents such as 'Cortisol'. BIONOTE's booth also featured lectures by prominent veterinarians (Dr. Elizabeth Rozanski, Tufts Cummings School of Veterinary Medicine / Dr. Luis Tarrido, Eden Veterinary Clinic / Dr. Geri Lake-Bakaar, Evolution Veterinary Specialists) on the subject of their experience of applying Vcheck F products in clinical settings and their experience of evaluating the products. A BIONOTE spokesperson stated "To increase awareness and market share in the U.S., we are actively participating in conferences to meet and promote to veterinarians in person, with the support of KOTRA's global support project for mid-sized companies" and that "We will continue to participate in various academic conferences and exhibitions across the United States to increase brand awareness". Meanwhile, BIONOTE successfully launched three types of Equine-related biomarker products (Foal IgG, Progesterone, SAA) last year to target the U.S. market, and plans to lead the Equine diagnostic reagent market by developing additional Equine products this year. 

    2024.01.19
    BIONOTE's Vcheck D-dimer, a More Sensitive Biomarker for Blood Clot Screening

    ▶ D-dimer diagnostic kit for quantitative results in-house The sensitivity of BIONOTE's D-dimer kit, which can be used with the immunoassay analyzer Vcheck (V200 and V2400), has increased even more.  During the secondary hemostasis of the blood clotting process, fibrin clots are produced, and they are degraded by plasmids into fibrin degradation products (FDP). D-dimer is one of the final degradation products of these processes and is considered a highly sensitive biomarker for coagulation activity.The biomarker can be used to detect excessive thrombus formation early, which can aid in screening for diseases related to thrombus, such as thromboembolism (TE) or disseminated intravascular coagulation (DIC).D-dimer can be clinically utilized by testing patients with risk factors that may cause thromboembolism such as cancer, sepsis, pancreatitis, vascular disease, or immune-mediated diseases. Furthermore, it can also be utilized for preemptively preventing emergencies after surgery or to monitor the progress and effectiveness of antithrombotic therapy. A high correlation (R²=0.9289) was confirmed for the Vcheck measurements, in comparison with third-party analyzers with proven validity in canine D-dimer measurements, proving the Vcheck result's validity. A BIONOTE spokesperson stated, "The ability to screen for thrombus was improved by upgrading the performance (sensitivity) of the Vcheck D-dimer kit, which was first launched 5 years ago".The Vcheck analyzer can measure a total of 30 biomarkers including inflammation markers (CRP, SAA), pancreatitis markers (cPL, fPL), cardiac disease markers (NT-proBNP, Troponin I), kidney disease markers (SDMA), hormones (T4, TSH, Cortisol), antibody titer tests, as well as D-dimer.

    2024.01.16
    Clinical Utility of NT-proBNP Cardiac Biomarker in Diagnosis

    ▶ A webinar on the topic of 'Clinical Utility of NT-proBNP Cardia Biomarker in Diagnosis' was held on the 1st of December▶ Part two in the webinar series is planned for the 20th of December on the topic of 'Point-of-Care NT-proBNP in Diagnosis and Management of Cardiac Disease'The speaker of this webinar, Dr. Geri Lake-Bakaar, introduced Cardiac Biomarkers (NT-proBNP) which are greatly useful in the diagnosis of heart disease and evaluate patients' prognosis in dogs and cats.Dr. Geri Lake-Bakaar is an alumnus of Harvard and Cornell University and in 2013, she became a Board-certified veterinary specialist in Cardiology (DACVIM, Cardiology) from UC Davis. NT-proBNP can be used to screen for Occult Cardiomyopathy which doesn't have any clinical symptoms and especially be useful as a preanesthetic test or when the patient displays heart murmurs. Further, it can also be useful in determining whether the respiratory symptoms of the patient are caused by congestive heart failure or respiratory diseases.Increased levels of NT-proBNP in patients with heart disease are associated with impending heart failure, with a high probability of progressing to congestive heart failure in dogs above 1,500 pmol/L. In humans, NT-proBNP markers are also utilized clinically, and when the value decreases by more than 30%, the clinical prognosis can be determined to be good. On the other hand, when there is no change in the value or if there is an increase, it can be considered as an indicator of bad prognosis. However, the increased NT-proBNP levels could be due to heart failure, ischemia, and arrhythmia as well, so caution was advised in interpreting the results. In the case of commercially available qualitative measurement kits for feline NT-proBNP, while they can be used to exclude heart disease from the diagnostic differentials, it was emphasized that the results of quantitative tests should be used together with the qualitative results because false positives are common in quantitative tests. On the other hand, the NT-proBNP kit from BIONOTE Inc., which provides accurate quantitative results on-site in just a couple of minutes using the Vcheck equipment, was mentioned as a clinically useful method for diagnosis by Dr. Lake-Bakaar.  On Wednesday the 20th of December, Dr. Lake-Bakaar will hold the second part of the cardiac biomarker webinar series, specifically on the topic of 'Point-of-Care NT-proBNP in Diagnosis and Management of Cardiac Disease'. In this webinar, she will provide more detailed information on how NT-proBNP levels are useful in monitoring treatment plans in hospitalized patients of patients receiving outpatient treatments.The webinar is free for anyone to join through the QR code and will start at 10 am Korean Standard Time (KST). 

    2023.12.18
    BIONOTE, Presents on the Topic of POC PCR at the Korean Society of Veterinary Science Fall Academic Conference

    ▶ Presented on the topic of molecular diagnostics market trends and changes in POC PCR equipment technology▶ Announced plans to accelerate global business by expanding reagent parameters of Vcheck M10 amid expanding veterinary molecular diagnostics marketGlobal leader in Veterinary Diagnostics and Biological Raw Materials BIONOTE Inc., announced on the 8th of December, that they presented on the topic of POC PCR (Pointe of Care Polymerase Chain Reaction) at the 2023 Korean Society of Veterinary Science Fall Academic Conference, held at the Jeju International Convention Center on the 29th of November to 2nd of December.  At this year's conference, a total of 19 academic sessions were held under the theme of "Advanced Fusion and Technology of Veterinary Biomedical Research".   BIONOTE's resident DVM, Dr. Angela Moon, presented at the "Field Application fo Advanced Molecular Diagnostic Technology for Animal Diseases" session of Symposium 13, on the topic of "Point of Care Testing Application Trends of PCR In Companion Animal Disease Diagnosis".  The primary focus was on the market trends of molecular diagnostics in the global veterinary market and changes in Point of Care PCR equipment technology.    The global veterinary molecular diagnostics market size is expected to grow from 300 billion KRW in 2021 to 540 billion KRW by 2026, with an average annual growth of 10%.  In addition, 95% of all PCR tests are currently referred to diagnostic laboratories, and only about 5% are carried out using POC equipment. However, as improved POC PCR equipment continues to be developed, a significant change in the market share is expected within the next 5 years.    Vcheck M10, launched by BIONOTE in the second half of last year, is a Real-time PCR device that performs nucleic acid extraction, amplification, and results analysis all within an hour using a single device. It is also characterized by the ability to scale up depending on the needs of the customer, from specialized laboratories to small and large vet clinics, through the expansion of up to 8 channels. A BIONOTE spokesperson stated, " We plan on continuing to expand the reagent parameters to accelerate our global business growth" and "We are also planning to launch our Babesia gibsoni ​cartridge and enter the domestic market after acquiring the necessary regulatory clearance". 

    2023.12.08
    BIONOTE attends the largest veterinary conference in Latin America

    ▶ Attended the Congreso Veterinario de León, held in Mexico for 4 days between the 6th and 9th of September▶ Intends to continue to increase supply and service towards end-users... continue to increase M/S in Latin America Global leader in Veterinary Diagnostics and Biological Raw Materials BIONOTE Inc., announced today that they participated in Congreso Veterinario de León (CVDL), the largest veterinary conference in Latin America.The Conference was held in León, Mexico for 4 days between the 6th and 9th of September.CVDL is the largest veterinary conference in Latin America, held every year in León Mexico​ since 1995. This conference is a gathering of over 900 veterinary companies from all over South and Central Americas, including Mexico, as well as veterinarians from around the World, with over 30 academic seminars.  Through this conference, BIONOTE was able to promote their rapid diagnostic tests (RDTs), fluorescent immunoassay platform Vcheck F, Point of Care (POC) molecular diagnostic platform Vcheck M as well as the soon to be launched Vcheck C, the versatile high-throughput chemistry analyzer.  Furthermore, BIONOTE was able to receive valuable feedback and insight regarding their current products from the veterinarian end-users, as well as have meaningful discussions with BIONOTE's Latin American dealers regarding future plans and strategies to increase M/S & to successfuly launch the newest products.   A BIONOTE spokesperson commented that "the Latin American market is rapidly expanding" and that "BIONOTE will continue to not only provide excellent quality products, but to also provide the necessary training, academic support and services for the customers in order to strengthen our position in the Latin American market while increasing M/S". 

    2023.09.11
    BIONOTE signs supply agreement with one of the three largest distributors in the US

    BIONOTE signs supply agreement with one of the three largest distributors in US▶ Technology, performance, and marketability of BIONOTE's products highly valued... will continue to increase market share​Global leader in Veterinary Diagnostics and Biological Raw Materials BIONOTE Inc., announced on the 25th of April that they have signed a supply agreement with Covetrus, one of the three largest distributors in the United States, expanding their sales potential for animal diagnostics in the US market.Covetrus is one of the largest distributors of animal pharmaceuticals and diagnostic products in the world with revenue of over 4 billion USD, as of 2021, supplying products to North America, Europe, and Asia. Key customer bases include animal hospitals, clinics, pharmaceutical companies, pharmacies, and pet stores. Furthermore, they also provide medical information technology solutions, financial and management software for animal hospitals.BIONOTE plans to provide their veterinary fluorescent immunoassay series, 'Vcheck F', through this supply agreement. Vcheck F is a series of products, based on immunochromatic assay technology, capable of producing accurate results through the use of highly sensitive fluorescent materials. A total of 27 markers for cardiac diseases, inflammation, etc. can be tested quantitatively, as well as qualitatively using the Vcheck F series.BIONOTE plans to expand their presence in the market and increase sales of their various products, through cooperation with Covetrus for maximizing marketing and promotional activities.Dr. Byungki Cho, CEO of BIONOTE commented that "the supply agreement between Covetrus and BIONOTE is a testament to the excellence in technology, performance and marketability of BIONOTE's products" and that "BIONOTE will continue to strive to use this opportunity to increase the market share of our products in the US market".

    2023.04.26
    BIONOTE, continues expansion into global markets through 'Vcheck M10'

     DISCLAIMER: This news article is a direct translation of the original Korean article from Medipana News. BioNote Inc. does not claim any right to the article or claim any ownership.The translation was completed by BIONOTE Inc. only for the convenience of non-Korean speaking customers and BioNote Inc. does not seek to redistribute nor acquire profit from the translation.​BIONOTE announced on the 11th that they are in the process of expanding further into the global market through their Point of Care Molecular Diagnostic Analyzer, 'Vcheck M10' ("M10").M10 is an automatic analyzer that can perform both nucleic acid extraction and PCR, which previously needed to be performed separately using two different machines. The test procedure is simple enough for any veterinarians to perform on-site at the animal hospitals without separate prior training. The user can receive accurate PCR results through the M10 within an hour and removes the need to send samples to specialized labs to receive results, which can take up to 3 days.Furthermore, depending on the user's needs, they are able to customize how many channels they would like to use, up to a maximum of 8, making the M10 suitable for small hospitals, large hospitals and even labs.A BIONOTE Spokesperson commented that "The 'Canine Vector 8 Panel' recently released for the M10, has been received extremely well overseas with exponentially increasing sales numbers." and that "New sales have been recorded in countries such as Australia, Hong Kong and Mexico, with multiple European Countries in line to join the list soon as well."In addition, BIONOTE is aiming to develop and launch its 'Vcheck M Diarrhea 8 Panel' within the year, while also moving forward with international clinical evaluations in order to prove the excellence of their technology. Beyond that, they are also planning to expand into the livestock animal market through developing new tests for the M10 and expanding their catalog.Dr. Byung Ki Cho, CEO of BIONOTE, stated "It is our goal to rapidly increase our global market presence and grab hold of the veterinary POC PCR market by 2025 through our various test items" and that "Along with our new POC clinical chemistry analyzer 'Vcheck C', we will be able to lead the global market in providing total diagnostic solutions."Link to original article: https://www.medipana.com/article/view.php?news_idx=310544&sch_cate=F

    2023.04.11
    Bionote launches new Equine panels, eProgesterone and eSAA

    Bionote, a leading veterinary diagnostic company based in Korea, is introducing two new biomarkers, eProgesterone and eSAA, as a part of the Vcheck series.    Vcheck eProgesterone is an in vitro diagnostic test kit for the quantitative measurement of progesterone concentration in Equine serum and plasma. This test kit precisely quantifies the degree of elevation in progesterone levels in horses.    Progesterone plays a crucial role in the maintenance of pregnancy until 120 days of gestation when the placenta becomes the main source. In addition, measuring progesterone helps find out mare’s reproductive cycle and plan most effectively. Vcheck eProgesterone assay allows you to quickly analyze Equine progesterone in the field, evaluate corpus callosum in the early stages of pregnancy, and monitor progesterone during pregnancy. Vcheck eProgesterone: This one-step test procedure is easy to follow and provides fast results within 15 minutes using serum and plasma samples from horses.   Vcheck Equine SAA is an in vitro diagnostic test kit for the quantitative measurement of SAA concentration in Equine serum and plasma. This test kit precisely quantifies the degree of elevation in SAA levels in horses.   SAA concentration increases in response to several clinical conditions in horses, such as sepsis, viral infections, arthritis, gastrointestinal and reproductive disease. Also, its measurement is useful for monitoring the response to treatment. Vcheck Equine SAA assay allows early detection of the presence of inflammation, monitors the post-operative effects and recovery, and serial monitoring of the response to treatment. Vcheck Equine SAA: This one-step test procedure is easy to follow and provides fast results within 5 minutes using serum and plasma samples from horses.   Bionote will also be introducing Vcheck Foal IgG within the first half of 2023. If you are interested in Vcheck eProgesterone and/or Vcheck Equine SAA, please contact your local distributor or mail to [bionote@bionote.co.kr].  

    2023.03.27